BackAlexion Pharmaceuticals Overview
Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals PEG Ratio

Valuation check: ALXN's PEG ratio is 471.99, above the Healthcare sector average of 1.26.

Get informed when a big investor buys or sells

+ Follow

PEG Ratio

471.99

PEG Ratio

471.99

The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.

PEG Ratio (Comparison Companies)

Loading

PEG Ratio History

Loading

PEG Ratio Comparison

Loading

Alexion Pharmaceuticals (ALXN) FAQ

Alexion Pharmaceuticals (ALXN) currently reports a PEG ratio of 471.99. That is above the Healthcare sector average of 1.26. Use the charts on this page to explore Alexion Pharmaceuticals's PEG ratio history and peer comparisons.

Alexion Pharmaceuticals's PEG ratio of 471.99 is higher than the Healthcare sector average of 1.26. That is roughly 37441.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Alexion Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 471.99, ALXN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 471.99, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 1.26. From there, open related valuation or income-statement pages for Alexion Pharmaceuticals, and consider following ALXN for alerts when major investors trade the stock.

Alexion Pharmaceuticals is classified in the Healthcare sector. On PEG ratio, it currently shows 471.99 versus a sector average near 1.26. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALXN with unrelated industries.